Wall Street Analysts Predict a 36.09% Upside in Castle Biosciences (CSTL): Here’s What You Should Know
ZacksThe mean of analysts’ price targets for Castle Biosciences (CSTL) points to a 36.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.